Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients

Francesco Locatelli, Giuseppe Villa, Piergiorgio Messa, Armando Filippini, Giuseppe Cannella, Giacomo De Ferrari, Agostino Naso, Egidio Rossi, Marco Formica, Luigi Lombardi, Ugo Rotolo, Ferruccio Conte

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Although an erythropoiesis-stimulating agent (ESA) is most frequently administered intravenously for treatment of anemia in patients with chronic kidney disease who are on dialysis, few studies have compared the efficacy of different intravenous (i.v.) dosing schedules. Methods: This multicenter, phase IIIb, open-label, controlled study randomized 289 stable hemodialysis patients to continue with conventional dosing of i.v. epoetin alfa or darbepoetin, or to switch to once-weekly i.v. epoetin alfa at the same cumulative weekly starting dose, to maintain hemoglobin levels at 11.0-13.0 g/dL, and within 1.0 g/ dL of the baseline value. Hemoglobin levels and ESA doses were recorded every 4 weeks for 28 weeks. Results: Hemoglobin levels fell significantly and ESA doses increased significantly between baseline and week 28 (mean of week 16-28 values) in the once-weekly epoetin alfa group, compared with the conventional treatment group (p

Original languageEnglish
Pages (from-to)412-420
Number of pages9
JournalJournal of Nephrology
Volume21
Issue number3
Publication statusPublished - 2008

Keywords

  • Anemia
  • Chronic kidney disease
  • Dialysis
  • Epoetin alfa
  • Erythropoiesis-stimulating agent
  • Frequency of administration

ASJC Scopus subject areas

  • Nephrology

Fingerprint

Dive into the research topics of 'Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients'. Together they form a unique fingerprint.

Cite this